217 related articles for article (PubMed ID: 21892208)
1. GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.
Chu IM; Michalowski AM; Hoenerhoff M; Szauter KM; Luger D; Sato M; Flanders K; Oshima A; Csiszar K; Green JE
Oncogene; 2012 Apr; 31(16):2017-27. PubMed ID: 21892208
[TBL] [Abstract][Full Text] [Related]
2. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
Chen LC; Tu SH; Huang CS; Chen CS; Ho CT; Lin HW; Lee CH; Chang HW; Chang CH; Wu CH; Lee WS; Ho YS
Breast Cancer Res Treat; 2012 Aug; 134(3):989-1004. PubMed ID: 22434522
[TBL] [Abstract][Full Text] [Related]
3. A molecular role for lysyl oxidase in breast cancer invasion.
Kirschmann DA; Seftor EA; Fong SF; Nieva DR; Sullivan CM; Edwards EM; Sommer P; Csiszar K; Hendrix MJ
Cancer Res; 2002 Aug; 62(15):4478-83. PubMed ID: 12154058
[TBL] [Abstract][Full Text] [Related]
4. ELK3-GATA3 axis modulates MDA-MB-231 metastasis by regulating cell-cell adhesion-related genes.
Kim KS; Kim J; Oh N; Kim MY; Park KS
Biochem Biophys Res Commun; 2018 Apr; 498(3):509-515. PubMed ID: 29510139
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration.
Postovit LM; Abbott DE; Payne SL; Wheaton WW; Margaryan NV; Sullivan R; Jansen MK; Csiszar K; Hendrix MJ; Kirschmann DA
J Cell Biochem; 2008 Apr; 103(5):1369-78. PubMed ID: 17685448
[TBL] [Abstract][Full Text] [Related]
6. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition.
Yan W; Cao QJ; Arenas RB; Bentley B; Shao R
J Biol Chem; 2010 Apr; 285(18):14042-51. PubMed ID: 20189993
[TBL] [Abstract][Full Text] [Related]
7. P2Y2R activation by nucleotides released from the highly metastatic breast cancer cell MDA-MB-231 contributes to pre-metastatic niche formation by mediating lysyl oxidase secretion, collagen crosslinking, and monocyte recruitment.
Joo YN; Jin H; Eun SY; Park SW; Chang KC; Kim HJ
Oncotarget; 2014 Oct; 5(19):9322-34. PubMed ID: 25238333
[TBL] [Abstract][Full Text] [Related]
8. C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision.
Ma J; Liu C; Yang D; Song J; Zhang J; Wang T; Wang M; Xu W; Li X; Ding S; Zhan J; Zhang H
Sci China Life Sci; 2019 Sep; 62(9):1229-1242. PubMed ID: 31376015
[TBL] [Abstract][Full Text] [Related]
9. Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß.
Chu IM; Lai WC; Aprelikova O; El Touny LH; Kouros-Mehr H; Green JE
PLoS One; 2013; 8(4):e61125. PubMed ID: 23577196
[TBL] [Abstract][Full Text] [Related]
10. [Mechanism of lysyl oxidase (LOX) in breast cancer invasion and metastasis].
Liu JL; Wei W; Tang W; Jiang Y; Yang HW; Li JT
Zhonghua Yi Xue Za Zhi; 2012 May; 92(20):1379-83. PubMed ID: 22883193
[TBL] [Abstract][Full Text] [Related]
11. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.
Chou J; Lin JH; Brenot A; Kim JW; Provot S; Werb Z
Nat Cell Biol; 2013 Feb; 15(2):201-13. PubMed ID: 23354167
[TBL] [Abstract][Full Text] [Related]
12. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis.
Dydensborg AB; Rose AA; Wilson BJ; Grote D; Paquet M; Giguère V; Siegel PM; Bouchard M
Oncogene; 2009 Jul; 28(29):2634-42. PubMed ID: 19483726
[TBL] [Abstract][Full Text] [Related]
13. Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.
Boufraqech M; Zhang L; Nilubol N; Sadowski SM; Kotian S; Quezado M; Kebebew E
Clin Cancer Res; 2016 Sep; 22(17):4491-504. PubMed ID: 27029493
[TBL] [Abstract][Full Text] [Related]
14. Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion.
Santhanam AN; Baker AR; Hegamyer G; Kirschmann DA; Colburn NH
Oncogene; 2010 Jul; 29(27):3921-32. PubMed ID: 20498644
[TBL] [Abstract][Full Text] [Related]
15. GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis.
Shahi P; Wang CY; Chou J; Hagerling C; Gonzalez Velozo H; Ruderisch A; Yu Y; Lai MD; Werb Z
Oncogene; 2017 Oct; 36(40):5567-5575. PubMed ID: 28581515
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
Tkocz D; Crawford NT; Buckley NE; Berry FB; Kennedy RD; Gorski JJ; Harkin DP; Mullan PB
Oncogene; 2012 Aug; 31(32):3667-78. PubMed ID: 22120723
[TBL] [Abstract][Full Text] [Related]
17. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase.
Cox TR; Rumney RMH; Schoof EM; Perryman L; Høye AM; Agrawal A; Bird D; Latif NA; Forrest H; Evans HR; Huggins ID; Lang G; Linding R; Gartland A; Erler JT
Nature; 2015 Jun; 522(7554):106-110. PubMed ID: 26017313
[TBL] [Abstract][Full Text] [Related]
18. Lysyl oxidase is essential for hypoxia-induced metastasis.
Erler JT; Bennewith KL; Nicolau M; Dornhöfer N; Kong C; Le QT; Chi JT; Jeffrey SS; Giaccia AJ
Nature; 2006 Apr; 440(7088):1222-6. PubMed ID: 16642001
[TBL] [Abstract][Full Text] [Related]
19. The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells.
Bondareva A; Downey CM; Ayres F; Liu W; Boyd SK; Hallgrimsson B; Jirik FR
PLoS One; 2009; 4(5):e5620. PubMed ID: 19440335
[TBL] [Abstract][Full Text] [Related]
20.
Shahi P; Wang CY; Lawson DA; Slorach EM; Lu A; Yu Y; Lai MD; Gonzalez Velozo H; Werb Z
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3169-3174. PubMed ID: 28258171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
